A phase III, multicenter, double-blind, placebo controlled, non-inferiority study assessing the effects of ciclesonide metered dose inhaler 50 mg/day and 200 mg/day (ex-valve) administered once daily on growth in children with mild persistent asthma

Trial Profile

A phase III, multicenter, double-blind, placebo controlled, non-inferiority study assessing the effects of ciclesonide metered dose inhaler 50 mg/day and 200 mg/day (ex-valve) administered once daily on growth in children with mild persistent asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2006

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top